IL12B (Interleukin-12 subunit beta) variants and mutations
IL12B (also known as Interleukin-12 subunit beta) is a human protein-coding gene encoding an interleukin-12 subunit beta protein. It provides the p40 subunit shared by IL-12 and IL-23, linking innate immune activation to Th1 and Th17 responses. Biallelic loss-of-function variants impair IFN-gamma-mediated defense against mycobacteria and Salmonella, while therapeutic blockade is effective in several inflammatory diseases. This analysis covers 613 IL12B variants and mutations. Of these, 94% have computational variant effect predictions. Disease context includes psoriasis, Crohn disease, and psoriasis vulgaris. Example IL12B variants include Q5H, V7A, and V7D.
Variant analysis overview
- Gene: IL12B
- Protein: Interleukin-12 subunit beta
- UniProt accession: P29460
- Organism: Homo sapiens
- Variants analyzed: 613
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 382 unspecified-consequence records; 2 stop lost; 5 splice-region variants; 90 synonymous variants; 108 missense variants; 8 stop-gained variants; 14 frameshift variants; 1 in-frame deletions; 3 substitution
- Prediction scores: 579 variants have prediction scores (94% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: psoriasis, Crohn disease, psoriasis vulgaris, psoriatic arthritis, ulcerative colitis, inflammatory bowel disease, immune system disorder, skin disorder, seborrheic dermatitis, erythematosquamous dermatosis, Oral ulcer, type 2 diabetes mellitus.
Protein structure and variant hotspots
- Protein features: 2 domains; 3 post-translational modification sites.
- Structural context: 319 variants have structural context.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable IL12B variants
Examples include Q5H, V7A, V7D, V7G, I8M, I8T, I8V, W10*. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Q5H (p.Gln5His), ExAC rs749205262, TOPMed rs749205262, gnomAD rs749205262, REVEL 0.04, MetaLR 0.05
- V7A (p.Val7Ala), TOPMed rs1754197608, REVEL 0.05, AlphaMissense 0.09
- V7D (p.Val7Asp), rs1754197608, ClinGen CA362038671, ClinVar RCV003587987, REVEL 0.19, AlphaMissense 0.09, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- V7G (p.Val7Gly), rs1754197608, ClinGen CA362038667, ClinVar RCV003194339, AlphaMissense 0.09, MetaLR 0.05, Uncertain significance, Inborn genetic diseases
- I8M (p.Ile8Met), rs769479312, ClinGen CA3538906, ClinVar RCV003110434, ExAC rs769479312, AlphaMissense 0.09, MetaLR 0.05, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- I8T (p.Ile8Thr), Ensembl rs372473387
- I8V (p.Ile8Val), TOPMed rs1754197494, MetaLR 0.05, MetaSVM -1.02
- W10* (p.Trp10Ter), rs763190982, ClinGen CA3538904, ClinVar RCV001050613, ExAC rs763190982, CADD 35.00, Pathogenic
- W10C (p.Trp10Cys), rs763190982, ClinGen CA3538903, ClinVar RCV002016361, ExAC rs763190982, REVEL 0.08, MetaLR 0.03, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- F11S (p.Phe11Ser), ExAC rs754651345, gnomAD rs754651345, MetaLR 0.11, MetaSVM -0.86
- S12P (p.Ser12Pro), gnomAD rs1328015123, REVEL 0.22, MetaLR 0.08
- S12F (p.Ser12Phe), rs754651345, []
- V14F (p.Val14Phe), ExAC rs779736965, TOPMed rs779736965, gnomAD rs779736965, REVEL 0.14, MetaLR 0.05
- V14I (p.Val14Ile), NCI-TCGA Cosmic COSV5145, Variant assessed as somatic; moderate impact.
- L16V (p.Leu16Val), TOPMed rs1754196689
- A17V (p.Ala17Val), rs1033790517, NCI-TCGA Cosmic COSV9918, TOPMed rs1033790517, gnomAD rs1033790517, REVEL 0.03, MetaLR 0.03, Variant assessed as somatic; moderate impact.
- S18Y (p.Ser18Tyr), NCI-TCGA TCGA novel, MetaLR 0.11, MetaSVM -0.97, Variant assessed as somatic; moderate impact.
- P19L (p.Pro19Leu), NCI-TCGA TCGA novel, Ensembl rs1754196408, REVEL 0.15, MetaLR 0.07, Variant assessed as somatic; moderate impact.
- P19S (p.Pro19Ser), NCI-TCGA TCGA novel, REVEL 0.12, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- V21M (p.Val21Met), rs750901737, ClinGen CA3538898, ClinVar RCV001295640, ExAC rs750901737, REVEL 0.04, MetaLR 0.01, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- I23M (p.Ile23Met), ExAC rs765772946, gnomAD rs765772946, REVEL 0.03, MetaLR 0.02
- I23T (p.Ile23Thr), gnomAD rs1395077837, MetaLR 0.05, MetaSVM -1.08
- W24C (p.Trp24Cys), rs1562114938, ClinGen CA362038399, ClinVar RCV002829203, Ensembl rs1562114938, REVEL 0.42, MetaLR 0.16, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- W24R (p.Trp24Arg), rs762144588, ClinGen CA3538896, ClinVar RCV000795785, ExAC rs762144588, REVEL 0.47, MetaLR 0.14, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- E25D (p.Glu25Asp), NCI-TCGA Cosmic COSV9918, Variant assessed as somatic; moderate impact.
- E25V (p.Glu25Val), NCI-TCGA Cosmic COSV9918, MetaLR 0.07, MetaSVM -1.02, Variant assessed as somatic; moderate impact.
- L26P (p.Leu26Pro), rs754181875, NCI-TCGA Cosmic COSV5145, ExAC rs754181875, gnomAD rs754181875, REVEL 0.40, MetaLR 0.18, Variant assessed as somatic; moderate impact.
- K27Q (p.Lys27Gln), rs980443442, ClinGen CA129831072, ClinVar RCV002015585, TOPMed rs980443442, REVEL 0.04, MetaLR 0.02, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- V30A (p.Val30Ala), rs1754133509, ClinGen CA362037097, ClinVar RCV002766988, TOPMed rs1754133509, REVEL 0.27, MetaLR 0.14, Uncertain significance, Inborn genetic diseases
- V33I (p.Val33Ile), rs3213096, ClinGen CA3538882, ClinVar RCV000545923, ClinVar RCV003431112, REVEL 0.14, MetaLR 0.05, Benign, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- L35S (p.Leu35Ser), TOPMed rs1469792164, gnomAD rs1469792164, REVEL 0.04, MetaLR 0.04
- L35P (p.Leu35Pro), rs757751382, []
- W37G (p.Trp37Gly), gnomAD rs1177833515, REVEL 0.35, MetaLR 0.11
- W37R (p.Trp37Arg), gnomAD rs1177833515, REVEL 0.40, MetaLR 0.14
- Y38H (p.Tyr38His), rs1232713153, NCI-TCGA Cosmic COSV5145, TOPMed rs1232713153, REVEL 0.07, MetaLR 0.01, Variant assessed as somatic; moderate impact.
- P39A (p.Pro39Ala), rs779340279, ClinGen CA3538879, ClinVar RCV003070091, ExAC rs779340279, REVEL 0.14, MetaLR 0.06, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- P39L (p.Pro39Leu), rs757751382, ClinGen CA3538878, ClinVar RCV002013484, ExAC rs757751382, REVEL 0.06, MetaLR 0.04, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- D40G (p.Asp40Gly), TOPMed rs1438401438, gnomAD rs1438401438, REVEL 0.16, MetaLR 0.04
- A41V (p.Ala41Val), TOPMed rs1251171357, gnomAD rs1251171357, REVEL 0.14, MetaLR 0.05
- P42A (p.Pro42Ala), TOPMed rs1754132622, REVEL 0.07, MetaLR 0.03
- G43A (p.Gly43Ala), NCI-TCGA Cosmic COSV5145, NCI-TCGA Cosmic COSV9918, Variant assessed as somatic; moderate impact.
- G43E (p.Gly43Glu), NCI-TCGA Cosmic COSV5145, NCI-TCGA Cosmic COSV9918, Variant assessed as somatic; moderate impact.
- G43R (p.Gly43Arg), rs144020395, ESP rs144020395, ExAC rs144020395, TOPMed rs144020395, REVEL 0.30, MetaLR 0.24, Uncertain significance, Inborn genetic diseases
- E44* (p.Glu44Ter), NCI-TCGA Cosmic COSV9918, Variant assessed as somatic; high impact.
- M45I (p.Met45Ile), TOPMed rs1253573493, gnomAD rs1253573493, REVEL 0.07, MetaLR 0.04
- M45T (p.Met45Thr), rs1192156895, ClinGen CA362036830, ClinVar RCV001068636, TOPMed rs1192156895, REVEL 0.01, MetaLR 0.01, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- V46L (p.Val46Leu), ExAC rs756413190, gnomAD rs756413190
- V46M (p.Val46Met), ExAC rs756413190, gnomAD rs756413190, REVEL 0.28, MetaLR 0.23
- V47D (p.Val47Asp), TOPMed rs1191638507, REVEL 0.22, MetaLR 0.06
- V47F (p.Val47Phe), rs563294089, ClinGen CA3538872, ClinVar RCV001883371, 1000Genomes rs563294089, REVEL 0.23, MetaLR 0.09, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- V47I (p.Val47Ile), 1000Genomes rs563294089, ExAC rs563294089, TOPMed rs563294089, gnomAD rs563294089, REVEL 0.08, MetaLR 0.07, Uncertain significance
- T49I (p.Thr49Ile), TOPMed rs56347721, gnomAD rs56347721, REVEL 0.19, MetaLR 0.13
- T49N (p.Thr49Asn), NCI-TCGA TCGA novel, REVEL 0.15, MetaLR 0.14, Variant assessed as somatic; moderate impact.
- C50Y (p.Cys50Tyr), rs1754131954, ClinGen CA362036738, ClinVar RCV001304211, Ensembl rs1754131954, REVEL 0.56, MetaLR 0.50, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- D51A (p.Asp51Ala), gnomAD rs974315484, REVEL 0.08, MetaLR 0.05, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- T52N (p.Thr52Asn), rs140131034, ESP rs140131034, TOPMed rs140131034, gnomAD rs140131034, REVEL 0.09, MetaLR 0.10, Variant assessed as somatic; moderate impact.
- P53A (p.Pro53Ala), rs183111978, ClinGen CA3538871, ClinVar RCV004404933, 1000Genomes rs183111978, REVEL 0.10, MetaLR 0.02, Uncertain significance, Inborn genetic diseases
- P53H (p.Pro53His), NCI-TCGA Cosmic COSV5145, MetaLR 0.05, MetaSVM -1.05, Variant assessed as somatic; moderate impact.
- P53L (p.Pro53Leu), NCI-TCGA Cosmic COSV5145, gnomAD rs1754131707, REVEL 0.12, MetaLR 0.04, Variant assessed as somatic; high impact.
- P53S (p.Pro53Ser), 1000Genomes rs183111978, ExAC rs183111978, TOPMed rs183111978, gnomAD rs183111978, REVEL 0.07, MetaLR 0.02, Uncertain significance
- D56G (p.Asp56Gly), TOPMed rs1754131654, MetaLR 0.04, MetaSVM -1.03
- G57D (p.Gly57Asp), gnomAD rs1382273910, REVEL 0.07, MetaLR 0.02
- G57V (p.Gly57Val), gnomAD rs1382273910, REVEL 0.07, MetaLR 0.03
- T59A (p.Thr59Ala), TOPMed rs1754131441
- T59I (p.Thr59Ile), ExAC rs765124116, gnomAD rs765124116, REVEL 0.03, MetaLR 0.05
- W60* (p.Trp60Ter), TOPMed rs1324674540, gnomAD rs1324674540, CADD 36.00
- T61A (p.Thr61Ala), ExAC rs761837865, TOPMed rs761837865, gnomAD rs761837865
- T61N (p.Thr61Asn), rs2113030372, ClinGen CA362036468, ClinVar RCV001954204, Ensembl rs2113030372, REVEL 0.20, MetaLR 0.15, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- L62S (p.Leu62Ser), TOPMed rs1373603679
- Q64* (p.Gln64Ter), gnomAD rs1754131090, CADD 26.40
- Q64H (p.Gln64His), Ensembl rs1754130920, REVEL 0.07, MetaLR 0.05
- Q64R (p.Gln64Arg), ESP rs150659914, TOPMed rs150659914, gnomAD rs150659914, REVEL 0.05, MetaLR 0.04
- S65R (p.Ser65Arg), NCI-TCGA Cosmic COSV9918, ExAC rs768578364, TOPMed rs768578364, gnomAD rs768578364, REVEL 0.00, MetaLR 0.03, Variant assessed as somatic; moderate impact.
- S66N (p.Ser66Asn), rs746799998, ClinGen CA3538866, ClinVar RCV003079205, ExAC rs746799998, REVEL 0.05, MetaLR 0.06, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- S66R (p.Ser66Arg), TOPMed rs1241195275, gnomAD rs1241195275, REVEL 0.03, MetaLR 0.05
- E67A (p.Glu67Ala), rs1350168012, ClinGen CA362036298, ClinVar RCV001227278, TOPMed rs1350168012, AlphaMissense 0.11, MetaLR 0.06, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- E67D (p.Glu67Asp), rs986782158, ClinGen CA362036289, ClinVar RCV002618501, TOPMed rs986782158, REVEL 0.01, MetaLR 0.04, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- E67G (p.Glu67Gly), TOPMed rs1350168012, MetaLR 0.04, MetaSVM -1.03, Uncertain significance
- E67K (p.Glu67Lys), NCI-TCGA TCGA novel, TOPMed rs1754130621, REVEL 0.01, MetaLR 0.03, Variant assessed as somatic; moderate impact.
- V68F (p.Val68Phe), TOPMed rs1015688626, gnomAD rs1015688626, REVEL 0.06, MetaLR 0.05
- L69I (p.Leu69Ile), Ensembl rs1469648879
- G70S (p.Gly70Ser), rs201684769, ClinGen CA3538865, ClinVar RCV004404934, 1000Genomes rs201684769, REVEL 0.25, MetaLR 0.15, Uncertain significance, Inborn genetic diseases
- G72C (p.Gly72Cys), gnomAD rs1754127107, REVEL 0.59, MetaLR 0.19
- K73Q (p.Lys73Gln), TOPMed rs1281723065, gnomAD rs1281723065, REVEL 0.17, MetaLR 0.13
- T74I (p.Thr74Ile), ExAC rs745410494, TOPMed rs745410494, gnomAD rs745410494
- T74N (p.Thr74Asn), ExAC rs745410494, TOPMed rs745410494, gnomAD rs745410494
- T74P (p.Thr74Pro), Ensembl rs1584755089
- L75V (p.Leu75Val), Ensembl rs1562113610, REVEL 0.24, MetaLR 0.17
- T76I (p.Thr76Ile), rs1554157031, ClinGen CA362036046, ClinVar RCV000652139, TOPMed rs1554157031, REVEL 0.21, MetaLR 0.07, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- T76P (p.Thr76Pro), Ensembl rs1584755081
- T76S (p.Thr76Ser), Ensembl rs1584755081, MetaLR 0.08, MetaSVM -1.08
- I77T (p.Ile77Thr), gnomAD rs1260872062, REVEL 0.19, MetaLR 0.11
- I77V (p.Ile77Val), ExAC rs778518679, gnomAD rs778518679, REVEL 0.03, MetaLR 0.04
- Q78H (p.Gln78His), TOPMed rs1469344841
- Q78K (p.Gln78Lys), TOPMed rs1183284812
- Q78P (p.Gln78Pro), TOPMed rs1361534479, REVEL 0.16, MetaLR 0.06
- E81G (p.Glu81Gly), 1000Genomes rs540842370, ExAC rs540842370, gnomAD rs540842370, REVEL 0.29, MetaLR 0.15
- G83E (p.Gly83Glu), NCI-TCGA TCGA novel, REVEL 0.01, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- G83R (p.Gly83Arg), rs756537897, ClinGen CA3538858, ClinVar RCV000652137, ExAC rs756537897, REVEL 0.01, MetaLR 0.04, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- G83V (p.Gly83Val), TOPMed rs1460145972, MetaLR 0.03, MetaSVM -1.02
- A85D (p.Ala85Asp), NCI-TCGA TCGA novel, MetaLR 0.19, MetaSVM -0.83, Variant assessed as somatic; moderate impact.
- G86C (p.Gly86Cys), Ensembl rs955389274
- Q87* (p.Gln87Ter), rs1562113567, ClinGen CA362035708, ClinVar RCV000692446, TOPMed rs1562113567, CADD 35.00, Pathogenic
- Q87H (p.Gln87His), rs2480209172, ClinGen CA362035693, ClinVar RCV002925723, REVEL 0.03, MetaLR 0.03, Uncertain significance, Inborn genetic diseases
- Q87R (p.Gln87Arg), TOPMed rs868595228
- T89I (p.Thr89Ile), ExAC rs753044197, gnomAD rs753044197, MetaLR 0.12, MetaSVM -1.03
- C90R (p.Cys90Arg), TOPMed rs1307665997, gnomAD rs1307665997, REVEL 0.61, MetaLR 0.43
- C90S (p.Cys90Ser), TOPMed rs1307665997, gnomAD rs1307665997, REVEL 0.57, MetaLR 0.43
- C90Y (p.Cys90Tyr), TOPMed rs1754125154, MetaLR 0.45, MetaSVM -0.07
- H91Y (p.His91Tyr), rs2113030116, ClinGen CA362035588, ClinVar RCV001883324, Ensembl rs2113030116, AlphaMissense 0.09, MetaLR 0.06, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- G93E (p.Gly93Glu), Ensembl rs267600520, REVEL 0.06, MetaLR 0.05
- G93R (p.Gly93Arg), TOPMed rs1393242788
- G94S (p.Gly94Ser), Ensembl rs1754124724
- E95D (p.Glu95Asp), rs751689646, ClinGen CA3538854, ClinVar RCV001958452, ClinVar RCV005854126, REVEL 0.04, MetaLR 0.05, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- E95K (p.Glu95Lys), rs56287471, ClinGen CA3538855, ClinVar RCV000652143, ClinVar RCV003945666, REVEL 0.01, MetaLR 0.02, Conflicting interpretations, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- V96A (p.Val96Ala), TOPMed rs1480947259
- V96F (p.Val96Phe), ESP rs368468349, ExAC rs368468349, TOPMed rs368468349, gnomAD rs368468349, REVEL 0.05, MetaLR 0.07, Uncertain significance, Inborn genetic diseases
- V96G (p.Val96Gly), TOPMed rs1480947259
- V96I (p.Val96Ile), ESP rs368468349, ExAC rs368468349, TOPMed rs368468349, gnomAD rs368468349
- S98I (p.Ser98Ile), ExAC rs763062544, gnomAD rs763062544
- S98N (p.Ser98Asn), ExAC rs763062544, gnomAD rs763062544, MetaLR 0.04, MetaSVM -1.02
- S98R (p.Ser98Arg), gnomAD rs1431364350, REVEL 0.25, MetaLR 0.15
- H99L (p.His99Leu), Ensembl rs1010779225, REVEL 0.14, MetaLR 0.04
- H99R (p.His99Arg), NCI-TCGA TCGA novel, MetaLR 0.04, MetaSVM -1.01, Variant assessed as somatic; moderate impact.
- S100L (p.Ser100Leu), rs144694601, ClinGen CA3538851, ClinVar RCV000813296, 1000Genomes rs144694601, REVEL 0.01, MetaLR 0.04, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- L101F (p.Leu101Phe), rs200722574, ClinGen CA3538849, ClinVar RCV000821979, ExAC rs200722574, REVEL 0.02, MetaLR 0.04, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- L101H (p.Leu101His), TOPMed rs1474450966
- L103M (p.Leu103Met), TOPMed rs1217551438, gnomAD rs1217551438, REVEL 0.33, MetaLR 0.16
- L103P (p.Leu103Pro), TOPMed rs1754123043, REVEL 0.58, MetaLR 0.20
- K107E (p.Lys107Glu), Ensembl rs1754122841
- E108G (p.Glu108Gly), ExAC rs771727370, gnomAD rs771727370, REVEL 0.17, MetaLR 0.08
- E108Q (p.Glu108Gln), ExAC rs775325033, gnomAD rs775325033, REVEL 0.13, MetaLR 0.07
- D109G (p.Asp109Gly), Ensembl rs1584754968
- D109N (p.Asp109Asn), rs1395936414, NCI-TCGA Cosmic COSV9918, TOPMed rs1395936414, gnomAD rs1395936414, AlphaMissense 0.08, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- D109Y (p.Asp109Tyr), TOPMed rs1395936414, gnomAD rs1395936414, REVEL 0.10, AlphaMissense 0.08
- I111V (p.Ile111Val), ExAC rs773815651, gnomAD rs773815651, REVEL 0.07, MetaLR 0.04
- W112L (p.Trp112Leu), Ensembl rs1562113473, REVEL 0.16, MetaLR 0.05
- D115E (p.Asp115Glu), TOPMed rs1415417017
- D115N (p.Asp115Asn), NCI-TCGA Cosmic COSV5145, Ensembl rs1754122054, REVEL 0.13, MetaLR 0.07, Variant assessed as somatic; moderate impact.
- L117* (p.Leu117Ter), ESP rs375191855, ExAC rs375191855, gnomAD rs375191855
- D119G (p.Asp119Gly), NCI-TCGA TCGA novel, REVEL 0.04, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- D119N (p.Asp119Asn), ExAC rs748791854, TOPMed rs748791854, gnomAD rs748791854, REVEL 0.06, MetaLR 0.03
- D119Y (p.Asp119Tyr), ExAC rs748791854, TOPMed rs748791854, gnomAD rs748791854, REVEL 0.09, MetaLR 0.09, Uncertain significance, Inborn genetic diseases
- Q120H (p.Gln120His), NCI-TCGA Cosmic COSV5145, Variant assessed as somatic; moderate impact.
- Q120K (p.Gln120Lys), ExAC rs778309275, gnomAD rs778309275, REVEL 0.07, MetaLR 0.03
- K121* (p.Lys121Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- K121T (p.Lys121Thr), Ensembl rs1754121610, MetaLR 0.14, MetaSVM -0.67
- E122E (p.Glu122Glu), gnomAD 5-159322510-T-C, CADD 10.80
- P123A (p.Pro123Ala), rs780376200, ClinGen CA3538815, ClinVar RCV001905807, ExAC rs780376200, REVEL 0.02, MetaLR 0.06, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- P123L (p.Pro123Leu), gnomAD rs867476819, REVEL 0.05, MetaLR 0.07
- P123S (p.Pro123Ser), ExAC rs780376200, TOPMed rs780376200, REVEL 0.01, MetaLR 0.03, Uncertain significance
- P123T (p.Pro123Thr), gnomAD 5-159322509-G-T, REVEL 0.04, MetaLR 0.06
- K124R (p.Lys124Arg), rs199703726, ClinGen CA3538814, ClinVar RCV002609727, 1000Genomes rs199703726, REVEL 0.07, MetaLR 0.05, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- K124Q (p.Lys124Gln), gnomAD 5-159322506-T-G, REVEL 0.05, MetaLR 0.04
- N125I (p.Asn125Ile), TOPMed rs1161325734, gnomAD rs1161325734, REVEL 0.05, AlphaMissense 0.13, Uncertain significance
- N125S (p.Asn125Ser), rs1161325734, ClinGen CA362034486, ClinVar RCV001877981, TOPMed rs1161325734, AlphaMissense 0.13, MetaLR 0.03, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- N125T (p.Asn125Thr), TOPMed rs1161325734, gnomAD rs1161325734, MetaLR 0.04, MetaSVM -0.99, Uncertain significance
- N125K (p.Asn125Lys), gnomAD 5-159322501-A-C, REVEL 0.13, MetaLR 0.04
- K126R (p.Lys126Arg), gnomAD 5-159322499-T-C, REVEL 0.10, MetaLR 0.06
- T127A (p.Thr127Ala), NCI-TCGA Cosmic COSV5145, Variant assessed as somatic; moderate impact.
- T127I (p.Thr127Ile), TOPMed rs1356089881, MetaLR 0.04, MetaSVM -1.05
- T127T (p.Thr127Thr), rs1754109781, gnomAD 5-159322495-G-T, CADD 9.08
- T127P (p.Thr127Pro), gnomAD 5-159322497-T-G, REVEL 0.20, MetaLR 0.11
- F128* (p.Phe128Ter), rs867933096, ClinGen CA129828180, ClinVar RCV003747830, Pathogenic
- F128C (p.Phe128Cys), 1000Genomes rs183576218, ExAC rs183576218, gnomAD rs183576218, REVEL 0.28, MetaLR 0.12
- F128I (p.Phe128Ile), rs750634348, ClinGen CA3538813, ClinVar RCV001302400, ExAC rs750634348, REVEL 0.21, MetaLR 0.12, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- F128S (p.Phe128Ser), 1000Genomes rs183576218, ExAC rs183576218, gnomAD rs183576218, REVEL 0.28, MetaLR 0.10, Uncertain significance, Inborn genetic diseases
- L129I (p.Leu129Ile), NCI-TCGA Cosmic COSV9918, Variant assessed as somatic; moderate impact.
- L129V (p.Leu129Val), gnomAD rs1176118104, REVEL 0.06, MetaLR 0.05
- L129* (p.Leu129Ter), gnomAD 5-159322494-AG-A, CADD 28.60
- R130K (p.Arg130Lys), gnomAD rs1479334784, REVEL 0.03, MetaLR 0.01
- R130R (p.Arg130Arg), gnomAD 5-159322488-T-G, CADD 12.50
- C131S (p.Cys131Ser), gnomAD rs1235118140, REVEL 0.76, MetaLR 0.50
- C131C (p.Cys131Cys), rs757355295, gnomAD 5-159322483-G-A, CADD 0.92
- E132K (p.Glu132Lys), rs139186048, ClinGen CA3538808, ClinVar RCV003071639, ClinVar RCV003269419, REVEL 0.17, MetaLR 0.06, Uncertain significance, Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficie
- E132A (p.Glu132Ala), gnomAD 5-159322481-T-G, REVEL 0.15, MetaLR 0.11
- E132* (p.Glu132Ter), gnomAD 5-159322482-C-A, CADD 36.00
- A133V (p.Ala133Val), gnomAD 5-159322478-G-A, REVEL 0.37, MetaLR 0.22
- K134N (p.Lys134Asn), NCI-TCGA Cosmic COSV5145, REVEL 0.05, MetaLR 0.04, Variant assessed as somatic; moderate impact.
- N135D (p.Asn135Asp), gnomAD 5-159322473-T-C, REVEL 0.11, MetaLR 0.07
Public IL12B analysis runs
- IL12B analysis run — IL12B (613 variants) — completed 2026-08-19